Osteal Therapeutics is developing targeted pharmacological therapies for orthopedic infections, focusing on reducing the associated mortality and morbidity rates. Their approach aims to enhance treatment outcomes for patients and streamline the surgical process for orthopedic surgeons.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ZFounders
Product
Problem
Orthopedic infections carry high mortality and morbidity rates, leading to poor and unpredictable outcomes for patients. Current treatment options may not be sufficiently targeted or effective, resulting in prolonged recovery times and increased healthcare costs.
Solution
Osteal Therapeutics is developing targeted pharmacological therapies designed to treat orthopedic infections and their consequences. Their approach focuses on providing orthopedic surgeons with better tools to rapidly and reliably resolve infections, with the goal of improving patient outcomes and reducing the overall burden of musculoskeletal infections on patients, surgeons, and the healthcare system. The company's clinical programs are informed by a deep understanding of the patient journey and the needs of orthopedic surgeons.
Target Audience
The primary customers are orthopedic surgeons treating patients with musculoskeletal infections.
Features
- Development of targeted infection therapies for musculoskeletal infections
- Focus on reducing mortality, morbidity, and the cost of care associated with orthopedic infections
- Clinical programs designed with a deep understanding of the patient journey